title: Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications.
abstract: Chronic inflammatory diseases, depending upon the duration and severity, are frequently associated with an increased risk of developing cancer. A classic paradigm is the enhanced risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD). Carcinogenesis is a multifactorial process that involves accumulation of genetic defects, protein modification, and cell-matrix interaction. In this review, we discuss aspects of chronic inflammation in IBD that influence the development of CRC and highlight the key molecular mediators involved in this process. Also, we identify potential targets that could facilitate earlier detection of dysplasia. The targeted manipulation of specific molecules or pathways could provide opportunities for the development of therapeutic and chemopreventive interventions, which may prove effective in arresting the progression of colitis-associated cancer (CAC), with clinical implications.
authors.affiliation: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA. drgati@gmail.com
authors.forename: Gati A
authors.initials: GA
authors.lastname: Goel
authors.forename: Ahmed
authors.initials: A
authors.lastname: Kandiel
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Achkar
authors.forename: Bret
authors.initials: B
authors.lastname: Lashner
mesh_terms: D003092:Colitis / Q000150:complications; D015179:Colorectal Neoplasms / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control; D005109:Extracellular Matrix / Q000378:metabolism; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism; D054892:Metagenome; D019936:Probiotics / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000378:metabolism
chemical_list: D018836:Inflammation Mediators; D036341:Intercellular Signaling Peptides and Proteins; D011956:Receptors, Cell Surface; D020782:Matrix Metalloproteinases